Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q08AF3
UPID:
SLFN5_HUMAN
Alternative names:
-
Alternative UPACC:
Q08AF3; Q08AF2; Q8WU54; Q96A82
Background:
Schlafen family member 5 (SLFN5) is a protein that may play a crucial role in the differentiation of hematopoietic cells. This process is vital for the development of blood cells, indicating SLFN5's potential importance in maintaining healthy immune and circulatory systems.
Therapeutic significance:
Understanding the role of Schlafen family member 5 could open doors to potential therapeutic strategies. Its involvement in hematopoietic cell differentiation suggests that SLFN5 could be a target for enhancing blood cell production in various blood disorders.